# OnCo record paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011" ;
  schema:name "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors"@en ;
  schema:description "37 patients were re-biopsied when their EGFR drug stopped working. Some had the expected resistance mutation; five had turned into small-cell lung cancer. In three, the resistance disappeared when the drug was stopped."@en ;
  schema:url <https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1126/scitranslmed.3002003>, <https://pubmed.ncbi.nlm.nih.gov/21430269/> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1126/scitranslmed.3002003> ;
  schema:datePublished "2011"^^xsd:gYear ;
  schema:author "Sequist LV, Waltman BA, Dias-Santagata D, et al." ;
  onco:related <https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/>, <https://onco.cc/key-papers/paper-jamal-hanjani-tracerx-evolution-nsclc-nejm-2017/>, <https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/terms/ngs/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:institutions <https://onco.cc/institutions/mgh/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/histology/>, <https://onco.cc/pathways/clonal-evolution/> ;
  onco:people <https://onco.cc/people/lecia-sequist/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-preclinical-models/> ;
  onco:journals <https://onco.cc/journals/science-translational-medicine/> .